Exelixis
EXEL
#2358
Rank
$6.15 B
Marketcap
$21.12
Share price
0.62%
Change (1 day)
8.31%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of March 2024 : $2.12 B

According to Exelixis's latest financial reports the company has $2.12 B in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$2.26 B-9.02%
2022-12-31$2.48 B12.57%
2021-12-31$2.21 B17.64%
2020-12-31$1.87 B11.46%
2019-12-31$1.68 B30.95%
2018-12-31$1.28 B351.8%
2017-12-31$0.28 B219.04%
2016-12-31$89.31 M-163.43%
2015-12-31$-0.15 B22.62%
2014-12-31$-0.12 B-273.36%
2013-12-31$66.23 M-77.66%
2012-12-31$0.29 B227.07%
2011-12-31$90.63 M-139.69%
2010-12-31$-0.23 B39.46%
2009-12-31$-0.17 B191.01%
2008-12-31$-56.27 M-165.79%
2007-12-31$85.51 M-5.63%
2006-12-31$90.61 M58.15%
2005-12-31$57.29 M13.07%
2004-12-31$50.67 M-68.62%
2003-12-31$0.16 B-8.21%
2002-12-31$0.17 B-25.84%
2001-12-31$0.23 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
$70.02 B 3,190.40%๐Ÿ‡บ๐Ÿ‡ธ USA
$89.28 B 4,095.84%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.23 B 192.86%๐Ÿ‡บ๐Ÿ‡ธ USA
$82.20 B 3,762.92%๐Ÿ‡ซ๐Ÿ‡ท France
$37.63 B 1,668.55%๐Ÿ‡บ๐Ÿ‡ธ USA
$16.54 B 677.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$16.71 B 685.61%๐Ÿ‡ฌ๐Ÿ‡ง UK
$19.67 M-99.08%๐Ÿ‡บ๐Ÿ‡ธ USA
$28.84 M-98.64%๐Ÿ‡บ๐Ÿ‡ธ USA